Rationalizing 5000-Fold Differences in Receptor-Binding Rate Constants of Four Cytokines  by Pang, Xiaodong et al.
Biophysical Journal Volume 101 September 2011 1175–1183 1175Rationalizing 5000-Fold Differences in Receptor-Binding Rate Constants
of Four CytokinesXiaodong Pang, Sanbo Qin, and Huan-Xiang Zhou*
Department of Physics and Institute of Molecular Biophysics, Florida State University, Tallahassee, FloridaABSTRACT The four cytokines erythropoietin (EPO), interleukin-4 (IL4), human growth hormone (hGH), and prolactin (PRL)
all form four-helix bundles and bind to type I cytokine receptors. However, their receptor-binding rate constants span a 5000-fold
range. Here, we quantitatively rationalize these vast differences in rate constants by our transient-complex theory for protein-
protein association. In the transient complex, the two proteins have near-native separation and relative orientation, but have
yet to form the short-range specific interactions of the native complex. The theory predicts the association rate constant as
ka ¼ ka0 expðDGel=kBTÞ where ka0 is the basal rate constant for reaching the transient complex by random diffusion, and
the Boltzmann factor captures the rate enhancement due to electrostatic attraction. We found that the vast differences
in receptor-binding rate constants of the four cytokines arise mostly from the differences in charge complementarity among
the four cytokine-receptor complexes. The basal rate constants (ka0) of EPO, IL4, hGH, and PRL were similar (5.2 
105 M1s1, 2.4  105 M1s1, 1.7  105 M1s1, and 1.7  105 M1s1, respectively). However, the average electrostatic
free energies (DGe1) were very different (4.2 kcal/mol, 2.4 kcal/mol, 0.1 kcal/mol, and 0.5 kcal/mol, respectively, at ionic
strength ¼ 160 mM). The receptor-binding rate constants predicted without adjusting any parameters, 6.2  108 M1s1, 1.3 
107 M1s1, 2.0  105 M1s1, and 7.6  104 M1s1, respectively, for EPO, IL4, hGH, and PRL agree well with experimental
results. We uncover that these diverse rate constants are anticorrelated with the circulation concentrations of the cytokines, with
the resulting cytokine-receptor binding rates very close to the limits set by the half-lives of the receptors, suggesting that
these binding rates are functionally relevant and perhaps evolutionarily tuned. Our calculations also reproduced well-observed
effects of mutations and ionic strength on the rate constants and produced a set of mutations on the complex of hGH with its
receptor that putatively enhances the rate constant by nearly 100-fold through increasing charge complementarity. To quantify
charge complementarity, we propose a simple index based on the charge distribution within the binding interface, which shows
good correlation with DGe1. Together these results suggest that protein charges can be manipulated to tune ka and control bio-
logical function.INTRODUCTIONCytokines are a large family of small proteins that, by
binding to specific cell surface receptors, initiate signals
critical for cell proliferation, differentiation, and apoptosis.
Class-I helical cytokines form four-helix bundles. Erythro-
poietin (EPO), interleukin-4 (IL4), human growth hormone
(hGH), and prolactin (PRL) are well-known members of
this class. EPO is produced mainly in the adult kidney,
and is responsible for red blood cell production and
maintenance. IL4 is produced primarily by activated T-cells
and mast cells, and is involved in stimulation of activated
B-cells, proliferation of T-cells, and differentiation of
CD4þ T-cells into Th2 cells. The hGH is produced mainly
in the anterior pituitary gland; its function is to stimulate
growth, cell reproduction, and regeneration. PRL is also
produced in the anterior pituitary gland; it simulates the
mammary glands to produce milk and has other functions
including an essential role in the maintenance of immune
system functions.
To elucidate signaling mechanisms and develop thera-
peutic applications, the interactions of these four cytokinesSubmitted April 1, 2011, and accepted for publication June 8, 2011.
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two decades (1–18). All of them bind to type I cytokine
receptors. Each of these cytokines has two receptor binding
sites, referred to as site 1 and site 2. Initial binding to
a receptor molecule via the high-affinity site (Fig. 1, A–D)
primes the subsequent binding of a second receptor mole-
cule to the remaining site. The resulting dimerization of
the receptor molecules initiates the signaling cascade.
Despite these similarities, the association rate constants of
EPO, IL4, hGH, and PRL with their first receptor molecules,
EPO receptor (EPOR), IL4 alpha receptor (IL4Ra), hGH
receptor (hGHR), and PRL receptor (PRLR), vary widely:
4.0  108 M1s1 (6), 1.3  107 M1s1 (8), 3.2 
105 M1s1 (15), and 8.0  104 M1s1 (17), respectively
(at an ionic strength of 160 mM). Here, we use our recently
developed transient-complex theory for protein-protein
association (19–22) to quantitatively rationalize the 5000-
fold differences in receptor-binding rate constants among
the four cytokines, and highlight the role of protein charges
in controlling biological function via tuning association
rates.
The transient complex refers to the intermediate along the
binding pathway, in which the two associating proteins have
near-native separation and relative orientation, but have yetdoi: 10.1016/j.bpj.2011.06.056
FIGURE 1 Structures of the EPO-EPOR, IL4-IL4Ra, hGH-hGHR, and
PRL-PRLR high-affinity complexes. (A) The EPO-EPOR native complex.
EPO is shown as surface and EPOR as tube. (B) The IL4-IL4Ra native
complex. (C) The hGH-hGHR native complex. (D) The PRL-PRLR native
complex. (E) The EPO-EPOR transient-complex ensemble, as illustrated by
eight representative poses. In each pose EPOR is represented as a tube with
color varying from blue at the N-terminal to red at the C-terminal. (F) The
IL4-IL4Ra transient-complex ensemble. (G) The hGH-hGHR transient-
complex ensemble. (H) The PRL-PRLR transient-complex ensemble.
1176 Pang et al.to form the short-range specific interactions of the native
complex (20). The transient-complex theory predicts the
association rate constant as
ka ¼ ka0 exp
DGe1=kBT; (1)Biophysical Journal 101(5) 1175–1183where ka0 is the basal rate constant for reaching the transient
complex by random diffusion,DGe1 is the average electro-
static interaction free energy of the transient complex, kB is
the Boltzmann constant, and T is the absolute temperature.
Electrostatic attraction enhances the association rate by
increasing the probability of reaching the transient complex.
Equation 1 allows us to isolate the electrostatic contribution
to ka, via DG

e1, from the basal rate constant ka0. Our imple-
mentation of Eq. 1 is fully automated and free of adjustable
parameters.
EPO natively contains three N-linked glycans at positions
N24, N38, and N83 and one O-linked glycan at S126.
Previous studies demonstrated that desialylation of EPO
results in an increased EPOR affinity (2). The increase in
affinity is primarily due to an increase in the association
rate constant ka, with very little change in the dissociation
rate constant kd. Introduction of a single negative charge
on the protein surface has an effect similar to that of glyco-
sylation (6), suggesting that electrostatic interactions play
a critical role in EPO-EPOR binding. Our calculations based
on Eq. 1 found a significant electrostatic contribution to the
EPO-EPOR binding rate, enhancing the ka of nonglycosy-
lated EPO (NGE) by 1175-fold at ionic strength ¼
160 mM. The rate enhancement arose from strong electro-
static complementarity between EPO and EPOR, which
feature highly positive and negative electrostatic surfaces,
respectively. The calculated ka results agree well with exper-
imental data forNGEand twovariantswith the four glycosyl-
ation sites replaced either by negatively charged Glu or by
positively charge Lys, over a wide range of ionic strength.
Compared to EPO-EPOR binding, our calculations found
that electrostatic contributions progressively weaken for
IL4-IL4Ra and hGH-hGHR binding, and even become
mildly unfavorable for PRL-PRLR binding. In line with
these calculations, the electrostatic surfaces of IL4 and
IL4Ra show moderate complementarity, whereas those of
hGH and hGHR and of PRL and PRLR are largely mixed.
Therefore, the vast differences in association rate constants
of the four cytokine-receptor complexes are simply dictated
by the degree of electrostatic complementarity. To simplify
the calculation of this complementarity, we propose an
index based on the charge distribution within the binding
interface. Although a previous attempt by McCoy et al.
(23) using a charge distribution-based index to represent
electrostatic complementarity was unsuccessful, our charge
complementarity index shows good correlation with DGe1.
Charge mutations at numerous positions on both hGH and
hGHR were found to have minimal effect on ka (13–15).
Given that electrostatic interactions contribute little to the
hGH-hGHR association rate; this finding is now easy to
understand. Our calculations here on these mutations found
that they indeed do not significantly affect ka. However, the
results on the EPO-EPOR binding rate suggest that sig-
nificant electrostatic rate enhancement can be introduced
to hGH-hGHR binding through mutation. We found that
Receptor-Binding Rates of Four Cytokines 1177concurrent charge reversal at two positions in the hGHR
binding site on hGH, D171R and E174R, and at two posi-
tions in the hGH binding site on hGHR, R43E and
R217E, significantly increase charge complementarity, and
putatively increase the hGH-hGHR binding rate constant
by nearly 100-fold.
Cellular processes are always faced with competing path-
ways and are thus likely under kinetic control rather than
thermodynamic control (22). In particular, a given cytokine
receptor may bind its cytokine but may also be lost due to
degradation or other reasons. The receptor is useful only if
cytokine binding occurs first. The half-life of the receptor
therefore sets a lower limit for the pseudo-first order
receptor-binding rate constant, which is the product of the
bimolecular binding rate constant ka and the cytokine circu-
lation concentration. We find that the vastly different ka
values of the four cytokines studied here are compensated
by vastly different circulation concentrations, such that the
pseudo-first order rate constants are all close to the limits
set by the half-lives of the receptors. Therefore, the cyto-
kine-receptor binding rates appear to be evolutionarily tuned
to ensure that all the receptors produced would participate in
cytokine binding.THEORETICAL METHODS
Starting from the structure of the native complex, our implementation of the
transient-complex theory for calculating the protein-protein association rate
constant is fully automated and free of adjustable parameters (20,21). It
consists of three main components: i), generation of the transient-complex
ensemble; ii), calculation of the basal rate constant; and iii), calculation of
the electrostatic interaction free energyDGe1. We now briefly describe the
preparation of the native complex and the components of the transient-
complex theory.Structure preparation for native complexes
The structures of the EPO-EPOR, IL4-IL4Ra, hGH-hGHR, and PRL-
PRLR native complexes were from Protein Data Bank entries 1EER (4),
1IAR (9), 1A22 (14), and 3NPZ (18), respectively. Three of these complexes
consist of the receptor extracellular domain bound to site 1 of the cytokine,
but the IL4-IL4Ra complex involves site 2 instead (Fig. 1, A–D). Two
missing loops in hGHR were built by Modeler (24). All hydrogen atoms
were added and energy minimized by the AMBER program.
In addition to the wild-type complexes, a large number of mutations were
studied. These include EPO NGE mutants in which the four glycosylated
sites were replaced either by Glu or by Lys. These mutants were referred
to as NGE-Glu and NGE-Lys, respectively. Four charge reversal mutations
of IL4 (K77E, R81E, K84D, and R85E) and a large number of charge muta-
tions on the hGH-hGHR complex for which experimental ka data are avail-
able (8,13–15) were also studied. Finally, a variant hGH-hGHR complex,
containing double mutations D171R and E174R on hGH and double muta-
tions R43E and R217E on hGHR, was designed to increase ka. The replaced
side chains were optimized by energy minimization.Generation of transient-complex ensembles
The transient complex was identified with the outer boundary of the bound-
state energy well (19), after generating the interaction energy landscape
around the native complex in the six-dimensional space of relative transi-tion and relative rotation. For each complex, the cytokine subunit was fixed
in space. The relative translation of the receptor subunit was represented by
the displacement vector r, and the relative rotation was represented by
a body-fixed unit vector e and a rotation angle c around the vector. The
native complex has rh jrj ¼ 0 and c ¼ 0.
The short-range interaction energy around the native complex was repre-
sented by the total number Nc of contacts between two lists of representa-
tive atoms across the binding interface. In general, the value of Nc decreases
as the two subunits move apart; along the way the range of allowed c values
(i.e., those corresponding to clash-free poses) exhibits a sharp increase. The
value of Nc at the midpoint of this sharp transition, denoted as N

c , defined
the transient complex. That is, the transient-complex ensemble consisted of
all the poses with N ¼ Nc . The values of Nc were 44, 32, 61, and 58 for the
EPO-EPOR, IL4-IL4Ra, hGH-hGHR, and PRL-PRLR native complexes,
respectively. Using a total of 8  106 poses each for the four systems,
the corresponding values of Nc defining the transient complexes were deter-
mined to be 18, 13, 19, and 19, respectively.Calculation of basal rate constants by force-free
Brownian dynamics simulations
The basal rate of constant for reaching the transient complex by random
diffusion was obtained from Brownian dynamics simulations as previously
described (20). The translational diffusion constants of the proteins were
assigned according to their molecular mass (25). These were 10.3 A˚2/ns
and 9.4 A˚2/ns for EPO and EPOR; 10.9 A˚2/ns and 9.8 A˚2/ns for IL4 and
IL4Ra; 9.7 A˚2/ns and 9.4 A˚2/ns for hGH and hGHR; and 9.8 A˚2/ns and
9.4 A˚2/ns for PRL and PRLR. For each cytokine-receptor complex, 4000
Brownian dynamics trajectories were used to calculate ka0.Calculation of DGe1
As in previous studies (20,21,26), 100 poses from the transient-complex
ensemble were randomly selected to calculate DGe1. For each pose, the
electrostatic interaction free energy, DGel was calculated as (20,21,27)
DGel ¼ GelðcomplexÞ  GelðcytokineÞ  GelðreceptorÞ; (2)
where Gel is the total electrostatic free energy of a solute molecule. Here,
complex refers to a pose from the transient-complex ensemble. The average
of DGel over the 100 poses produced DG

e1.
Electrostatic calculations were done by the Adoptive Poisson-Boltzmann
Solver (APBS version 1.2) (28), with AMBER charges (29) and Bondi radii
(30). The full, nonlinear Poisson-Boltzmann equation was solved. The
dielectric constant of the solute molecule was set to 4, and the dielectric
constant of the solvent was set to 78.5, corresponding to a temperature of
300 K. Atomic charges were mapped to grid points with the cubic B-spline
discretization, with the chgm flag set to spl2. Following our previous studies
on protein-protein and protein-RNA association (20,21,27), the dielectric
boundary was specified as the van der Waals surface by setting the srfm
flag to mol and srad to 0. The range of ionic strength (I) was from 60 to
1010 mM.
Each APBS calculation started with a coarse grid with dimensions of
193  193  193 covering a volume of 288 A˚  288 A˚  288 A˚ around
the solute molecule with the single Debye-Hu¨ckel boundary condition.
The Poisson-Boltzmann equation was then solved on a fine grid with
dimensions of 193  193  193 covering a volume of 144 A˚  144 A˚ 
144 A˚ centered on the binding interface of the complex.Quantification of charge complementarity
Our charge complemtarity index (CCI) was based on the charge distribution
within the binding interface. Charged residues were represented by one orBiophysical Journal 101(5) 1175–1183
1178 Pang et al.two side-chain atoms: OD1 and OD2 for Asp, OE1 and OE2 for Glu; NZ for
Lys, and NH1 and NH2 for Arg. Charged atom pairs across the binding
interface of the native complex were collected with a 7-A˚ cutoff. These
pairs were grouped into four kinds: þ; þ; þþ; and  . The charge
complementarity index was then calculated as
CCI ¼

X
i
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dþ i

X
i
1
d þi

X
i
1
dþ þi
þ
X
i
1
d i

;
(3)
where dþ i , d
 þ
i , d
þ þ
i , and d
 
i denote atom-atom distances of the
charged pairs. The first term favors opposite-charge pairs going in one
direction, whereas the second term penalizes like-charge pairs. A protein
complex with many positive charges on one side of the interface and
many negative charges on the other has a high CCI score; mixed charges
on either side result in a low score; and the presence of charges with the
same sign on both sides of the interface results in a negative score.RESULTS
The focus of this study is the rate constants for forming the
high-affinity complexes of EPO, IL4, hGH, and PRL with
their respective receptors. The four cytokines all form
four-helix bundles, with Ca pairwise root mean-square
deviations (RMSD) ~3.5 A˚. The four receptors each consist
of two fibronectin-III domains and are also structurally
similar, with RMSD again ~3.5 A˚. The EPO-EPOR, hGH-
hGHR, and PRL-PRLR complexes superimpose to RMSD
~4 A˚, but the IL4-IL4Ra complex involves a different
binding site such that the orientation of IL4 is flipped
(Fig. 1, A–D). Despite the structural similarities, the associ-
ation rate constants of the four systems differ by 5000-fold
(6,8,15,17). We now quantitatively rationalize these vast
differences in ka.Transient complexes of the EPO-EPOR,
IL4-IL4Ra, hGH-HGHR, and PRL-PRLR pairs
Out of 8  106 poses each sampled around the EPO-
EPOR, IL4-IL4Ra, hGH-hGHR, and PRL-PRLR native
complexes, the transient complexes were determined. The
four transient-complex ensembles contained 21,317, 10,351,
28,720, and 7410 poses, respectively. Like the native com-
plexes, the transient complexes of these cytokine-receptor
systems are also similar (again the orientation of IL4 is
flipped). This is not surprising, because the transient com-
plexes are determined by the native complexes. In Fig. 1,
E–H, we display eight representative poses each from the
four transient complexes. The averages and standard
deviations of cytokine-receptor separations in the four tran-
sient complexes were 6.1 5 1.2 A˚, 5.3 5 0.9 A˚, 6.1 5
1.2 A˚, and 5.5 5 1.1 A˚. The relative rotations of the
subunits in the four transient complexes were also similar.
Relative to the cytokines, the body-fixed unit vectors of
the receptors were mostly restricted to cones spanning
30, 23, 20, and 30, respectively. The averages and
standard deviations of the rotation angles around the body-Biophysical Journal 101(5) 1175–1183fixed vectors were 7 5 15, 6 5 17, 17 5 10, and
65 13, respectively.Predicted binding rate constants at I ¼ 160 mM
The receptor-binding rate constants of EPO, IL4, hGH, and
PRL obtained by the transient-complex theory were 6.2 
108 M1s1, 1.3  107 M1s1, 2.0  105 M1s1, and
7.6  104 M1s1, respectively, at ionic strength ¼
160 mM. These compare favorably with the experimental
values, 4.0  108 M1s1 (6), 1.3  107 M1s1 (8),
3.2  105 M1s1 (15), and 8.0  104 M1s1 (17), respec-
tively. Our calculations thus rationalize the 5000-fold differ-
ences in ka in the four cytokine-receptor systems.
What accounts for the vast differences in ka? We found
the basal rate constants to be similar, 5.2  105 M1s1,
2.4  105 M1s1, 1.7  105 M1s1, and 1.7 
105 M1s1, respectively, for the EPO-EPOR, IL4-IL4Ra,
hGH-hGHR, and PRL-PRLR pairs. However, the values of
the average electrostatic free energy DGe1 were very
different, 4.2 kcal/mol, 2.4 kcal/mol, 0.1 kcal/mol,
and 0.5 kcal/mol, respectively, for the four systems. There-
fore, electrostatic interactions significantly enhance the
receptor binding rates of EPO and IL4 (1175-fold and
670-fold, respectively), have a negligible effect on hGH-
hGHR binding, and mildly retard the PRL-PRLR binding.
The differences in electrostatic contribution become
obvious when the electrostatic surfaces of the subunits in
the four systems are displayed. As shown in Fig. 2, A–D,
the receptor binding sites on EPO and IL4 feature mostly
positive electrostatic surfaces, which complement mostly
negative electrostatic surfaces of the cytokine binding sites
on EPOR and IL4Ra. This is a common feature of protein
complexes with significant electrostatic rate enhancement
(20). In contrast, the two sides of the interface in the
hGH-hGHR and PRL-PRLR complexes lack such electro-
static complementarity, with both of the two electrostatic
surfaces in each complex having mixed positive and nega-
tive regions (Fig. 2, E–H).Charge complementarity index
As the results presented above demonstrate, electrostatic
complementarity can provide significant enhancement of
protein-protein association rates. We wanted to capture
electrostatic complementarity without having to solve the
Poisson-Boltzmann equation for the electrostatic surfaces.
Here, we propose a charge complementarity index calculated
by simply collecting the charge pairs across the binding
interface within a distance cutoff. The CCI values for the
EPO-EPOR, IL4-IL4Ra, hGH-hGHR, and PRL-PRLR
complexes were 2.4, 0.5, –0.1, and –0.3, respectively, appar-
ently correlating well (R2 ¼ 0.89) with the corresponding
DGe1 values (4.2 kcal/mol,2.4 kcal/mol,0.1 kcal/mol,
and 0.5 kcal/mol) (see Fig. S1 in the Supporting Material).
FIGURE 2 Electrostatic surfaces of the subunits in the EPO-EPOR, IL4-
IL4Ra, hGH-hGHR, and PRL-PRLR complexes. (A) Electrostatic surface
of EPO, with the bound EPOR shown as yellow ribbon. (B) Electrostatic
surface of EPOR, with the bound EPO shown as cyan ribbon. The four
glycosylation sites, N24, N38, N83, and S126, are shown by the side chains
in green stick. (C) Electrostatic surface of IL4, with the bound IL4Ra
shown as yellow ribbon. (D) Electrostatic surface of IL4Ra, with the bound
IL4 shown as cyan ribbon. (E) Electrostatic surface of hGH, with the bound
hGHR shown as yellow ribbon. (F) Electrostatic surface of hGHR, with the
bound hGH shown as cyan ribbon. (G) Electrostatic surface of PRL, with
the bound PRLR shown as yellow ribbon. (H) Electrostatic surface of
PRLR, with the bound PRL shown as cyan ribbon. Electrostatic potential
ranging from –5 kBT/e to 5 kBT/e is presented in a red/white/blue spectrum.
Receptor-Binding Rates of Four Cytokines 1179We also tested this CCI on a set of 100 other complexes with
DGe1 values ranging from –7.1 to 3.4 kcal/mol. On this larger
set CCI also showed reasonable correlation with DGe1 (data
not shown).Effects of ionic strength and charge mutations
on EPO-EPOR binding rate
Experimentally it was observed that the EPO-EPOR associ-
ation rate constant ka reduced significantly, by 58-fold,
when the ionic strength increased from 160 to 1010 mM,
whereas the dissociation rate constant changed minimally
(6). Qualitatively this is consistent with our previous finding
(20,21,26,27) that the electrostatic enhancement of ka
decreases significantly with increasing ionic strength, as
mobile ions screen the electrostatic interactions between
the proteins. Fig. 3 shows that the measured ionic strength
dependence of ka is quantitatively reproduced well by our
calculations, for both NGE and the NGE-Glu mutant.
At I¼ 160 mM, the calculated ka of NGE-Glu is lower by
2.8-fold than the calculated ka of NGE. This difference also
compares favorably with the experimental counterpart,
3.4-fold (6). The four EPO glycosylation sites are located
on the periphery of the EPOR binding site. Replacement
by Glu residues at these sites will add negatively spots on
the mostly positive electrostatic surface facing EPOR.
Hence, the long-range electrostatic repulsion of these Glu
residues by the negative electrostatic surface of EPOR
accounts for the lower ka of NGE-Glu. In terms of electric
charges, the NGE-Glu mutant mimics a glycosylated EPO,
and the EPOR binding rate constants of these two variants
are also similar (6). Going from NGE-Glu to NGE corre-
sponds to desialylation, which was found to increase
EPO-EPOR binding affinity through increasing ka (2,6).
Our calculations on NGE-Glu and NGE here suggest that
the increased ka upon desialylation arises from removingFIGURE 3 Comparison of ionic-strength dependences of calculated and
experimental ka for NGE and NGE-Glu binding to EPOR. The calculated ka
results are shown as continuous curves, whereas the experimental ka results
(6) are shown as symbols connected by dashes.
Biophysical Journal 101(5) 1175–1183
1180 Pang et al.the negative charges on the sialyl groups, which otherwise
would encounter repulsion from EPOR.
If instead of Glu the glycosylation sites are replaced by
Lys, the positively charged residues are expected to enhance
the attraction to EPOR through long-range electrostatic
interactions. Our calculated ka of NGE-Lys at I ¼
160 mM was higher by 2.5-fold than that of NGE. Curi-
ously, the measured ka values of NGE-Lys and NGE were
essentially the same (6).Effects of charge mutations on IL4-IL4Ra
binding rate
In a previous study (20), we were able to reproduce experi-
mental results for the effects of ionic strength and charge
neutralizations on the IL4-IL4Ra association rate. These
charge neutralizations were found to have modest effects
(<1.5-fold reduction) in ka. Here we studied the effects of
charge reversals on IL4. The association rate constants of
the IL4 K77E, R81E, K84D, and R85E mutants were calcu-
lated to be 3.9  106 M1s1, 6.9  105 M1s1, 2.9 
106 M1s1, and 2.3  106 M1s1 (corresponding to
reduction in ka of 3.4-, 18.8-, 4.5-, and 5.7-fold), respec-
tively. These results compare favorably with the experi-
mental values, 4.4  106 M1s1, 3.2  106 M1s1,
2.4  106 M1s1, and 3.6  106 M1s1, respectively
(8). The reduction in ka is easily explained by the electro-
static surfaces. As shown in Fig. 2, C–D, the IL4Ra binding
site on IL4 has a mostly positive electrostatic surface, which
complements a mostly negative electrostatic surface of the
IL4 binding site on IL4Ra. Therefore, replacement of the
positively charged residues of IL4 by negatively charged
residues change favorable electrostatic interactions into
unfavorable ones.Effects of charge mutations on hGH-hGHR
binding rate
Effects on the hGH-hGHR binding rate by charge mutations
at numerous positions on both hGH and hGHR were found
to be minimal (less than twofold) (13–15). An affinity
matured hGH variant was found to achieve affinity enhance-
ment through a decrease in kd, with little effect on ka (15).
Qualitatively, these observations are explained by our
calculation result that electrostatic interactions contribute
very little to the hGH-hGHR binding rate. Our calculations
on these mutants confirmed that their ka values differ from
the counterpart of the wild-type complex by less than
twofold.A hGH-hGHR variant with putatively enhanced
binding rate
Despite the inability of the large number of mutations tested
so far (13–15) to produce significant rate enhancement, theBiophysical Journal 101(5) 1175–1183results on the EPO-EPOR binding rate suggest that signifi-
cant electrostatic rate enhancement can be introduced to
hGH-hGHR binding through mutation. As noted previously,
the main difference between the two systems is that EPO
and EPOR have mostly positive and mostly negative elec-
trostatic surfaces, respectively, across the binding interface,
whereas the electrostatic surfaces of both hGH and hGHR
have mixed positive and negative regions (Fig. 2, A, B, E,
and F). We therefore designed charge mutations that would
make one electrostatic surface (presumably that of hGH, to
mimic EPO) mostly positive and the other electrostatic
surface (presumably that of hGHR, to mimic EPOR) mostly
negative. Inspection of the hGH electrostatic surface around
the binding interface revealed that two negatively charged
residues, D171 and E174, give rise to a negative region
that is surrounded by a mostly positive periphery (Fig. 4,
A and B). We reversed the charges of these residues by
mutating them to Arg. Similarly, on the hGHR electrostatic
surface, a positive region due to R43 and R217 is sur-
rounded by a mostly negative periphery (Fig. 4, A and C).
We reversed these charges by mutating them to Glu. With
the charge reversal on these four residues in the hGH-
hGHR interface, the two proteins now have both strong local
electrostatic interactions (Fig. 4 D) and good complemen-
tary electrostatic surfaces (Fig. 4, E and F).
The designed hGH-hGHR mutant was found to have
significant attraction. The electrostatic interaction free
energy in the transient complex, DGe1, changed from
0.1 kcal/mol to 2.7 kcal/mol at I ¼ 160 mM. As a result,
the calculated ka changed from 2.0 105 M1s1, and 1.6
107 M1s1, an 83-fold increase. As expected, the designed
mutations also improved CCI, from –0.1 to 0.8, suggesting
that CCI might serve as a guide for designing mutants with
enhanced association rates.DISCUSSION
Protein-protein association is at the center of diverse bio-
logical processes ranging from enzyme catalysis/inhibition
to regulation of immune response by cytokines. The associ-
ation rates often play a critical role in such processes. There-
fore, theoretical prediction of the association rate constants
is of great importance (31). A widely used approach for
calculating ka is by simulating the translational and rota-
tional Brownian motion of the subunits (32–35). This ap-
proach often involves adjusting parameters for specifying
the conditions for association to achieve optimal agreement
with experimental results, thereby compromising the pre-
dictive power. Moreover, this approach is computationally
expensive (e.g., requiring ~11 weeks running on 10 8-core
Intel CPUs in a recent study (35)). Our approach based on
the transient-complex theory overcomes both of these obsta-
cles (19–22). Most importantly, the approach allows us to
tease out the contributions to ka, thus providing insight
into the control of association rate constants. This ability
FIGURE 4 Electrostatic surfaces of the wild-type hGH-hGHR complex
and the designed mutant. (A) The location of the four residues to be mutated
in the native complex. (B) The negative region, defined by a box with
dashed borders, on the hGH electrostatic surface around D171 and E174.
(C) The positive region, defined by a box with dashed borders, on the
hGHR electrostatic surface around R43 and R217. (D) The local interac-
tions of the mutated residues in the native complex. (E) The electrostatic
surface of the mutated hGH. Note the contrast of the boxed region here
and in B. (F) The electrostatic surface of the mutated hGHR. Note the
contrast of the boxed region here and in C. Electrostatic potential ranging
from –5 kBT/e to 5 kBT/e is presented in a red/white/blue spectrum.
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IL4Ra, hGH-hGHR, and PRL-PRLR systems. We have not
only quantitatively reproduced the observed 5000-fold
differences in rate constants without adjusting any parame-
ters, but also provided a physical explanation for the vast
rate differences.
Is there a physiological reason for the vast differences in
the receptor-binding rate constants of EPO, IL4, hGH, and
PRL? Rapid association of some proteins (e.g., barnase
and bastar) has been suggested to play a critical physiolog-
ical role (e.g., for self-defense) (31). There is no evidence
indicating that this is the case for the cytokine-receptor
systems studied here. On the other hand, the clearance of
receptors due to degradation or other reasons presentsanother limiting factor. That is, the receptors are useful
only if cytokine binding occurs before their clearance.
The half-life t1/2 of the receptor sets a lower limit, k1/2 h
1/t1/2 for the pseudo-first order receptor-binding rate
constant kaCcyt, where Ccyt is the cytokine circulation
concentration. One expects kaCcyt R k1/2. We now check
this expectation on the four cytokine-receptor systems
studied here.
EPO presents in the plasma at very low concentrations,
~0.8–4 pM (36), even though it stimulates the very fast
production of ~2.3 million red cells/s. With observed ka ¼
4.0  108 M1s1 (6), we find kaCcyt ¼ 3.2  104 s1.
The half-time of EPOR is ~1.5 h (37), correspondingly
k1/2 ¼ 1.9  104 s1. It thus seems that the pseudo-first
order rate constant kaCcyt is barely enough to pass the lower
limit set by the half-life of EPOR. To make this happen, the
high ka is required to accommodate the low Ccyt. The results
for the IL4- IL4Ra system are similar. The minimum IL4
concentration required of T-cell proliferation is ~20 pM
(38). With ka ¼ 1.3  107 M1s1 (8), we find kaCcyt ¼
2.6  104 s1. This is comparable to the limit k1/2 ¼
0.8  104 s1 set by the 3.5-h half-life of IL4Ra (39). In
contrast, the two slow binding cytokines are present at
much higher concentrations, both at ~10 nM (40,41). For
hGH-hGHR binding, with ka ¼ 3.2  105 M1s1 (15) we
find kaCcyt ¼ 3.2  103 s1, to be compared with the limit
k1/2 ¼ 0.6  103 s1 set by the 30-min half-life of hGHR
(42). For PRL-PRLR binding, with ka ¼ 8.0  104 M1s1
(17) we find kaCcyt ¼ 0.8  103 s1, to be compared with
the limit k1/2 ¼ 0.4  103 s1 set by the 40-min half-life of
PRLR (42). We thus observe that the 5000-fold differences
in ka of the four cytokine-receptor systems are inversely
correlated with a 10,000-fold variation in Ccyt. We further
conclude that the receptor-binding rate constants and the
circulation concentrations of the different cytokines are
evolutionarily tuned to ensure that all the receptors pro-
duced would participate in cytokine binding rather than
being wasted.
The design of mutants with higher association rates may
be important for the increased rates alone. Such designed
mutants have the additional advantage that the binding
affinity is also enhanced (assuming that the dissociation
rate constant is not adversely affected). Extensive muta-
tional studies on hGH and hGHR (13–15) have not produced
any mutant with a significantly enhanced ka but have
produced a mutant with enhanced binding affinity through
slowing down dissociation (15). Here, we designed an
hGH-hGHR mutant that is predicted to have nearly 100-
fold enhancement in ka. Our design strategy follows that
of Schreiber and co-workers (43,44), by focusing on charge
mutations around the interface. In the systems studied
by Schreiber and co-workers, the binding site on the first
subunit is dominated by one type of charge, whereas
the binding site on the second subunit contains mixed posi-
tive and negative charges. Therefore, they focused on theBiophysical Journal 101(5) 1175–1183
1182 Pang et al.latter binding site to introduce charges complementary to
those on the first subunit. In the hGH-hGHR complex
studied here, both binding sites contain mixed positive
and negative charges, explaining why previous mutational
studies failed to produce mutants with enhanced ka. Never-
theless, we were able to design double mutations on the two
subunits to produce two electrostatic surfaces that are
mostly positive and mostly negative, respectively. Our
design approach is expected to be applicable to many other
systems.
It has been suggested that rapid association is as impor-
tant as high affinity in the proper functioning of proteins
(31). Manipulating association rate constants of various
components thus presents unique opportunities for the
control of protein functions. The predictive power of our
transient-complex theory for calculating protein-protein
association rate constants have been demonstrated in
previous studies (20,21,27) and further demonstrated here
by our results on four cytokine-receptor systems. We also
designed a mutant of the hGH-hGHR complex with a puta-
tive 83-fold increase in association rate. To guide such
design, we have proposed a simple charge complementarity
index, based on the charge distribution around the binding
interface.
On the four cytokine-receptor systems themselves, many
questions remain. For example, the mechanisms by which
the binding of these cytokines to the extracellular domains
of their receptors transmits signals through cell membranes
are still unknown. The binding process studied here, form-
ing the high-affinity 1:1 complex, is only part of the mech-
anisms. It is known that a second receptor molecule
subsequently binds to the low-affinity second site of the
cytokine in the 1:1 complex, and it is the resulting dimeriza-
tion of the receptor molecules that initiates signaling (11).
Blocking the binding of the second receptor is a focus of
cytokine antagonist design (14,17,45–47). We plan to study
these downstream steps in the future.
In conclusion, we have applied the transient-complex
theory to quantitatively rationalize the 5000-fold differences
in receptor binding rate constants among four cytokines
and have provided a physical explanation for the vast
differences. The EPO-EPOR and IL4-IL4Ra complexes
have a mostly positive electrostatic surface on one side of
the interface and a mostly negative electrostatic surface on
the other, a feature common to protein complexes with
significant electrostatic rate enhancement. In contrast, the
electrostatic surfaces on both sides of the interface in the
hGH-hGHR and PRL-PRLR complexes have mixed posi-
tive and negative regions. We have uncovered that the vast
differences in ka are anticorrelated with the equally vast
differences in cytokine circulation concentration and
conclude that both are evolutionarily tuned. The vast differ-
ences in ka and other results presented here suggest that
protein charges can be manipulated to tune ka and control
biological function.Biophysical Journal 101(5) 1175–1183SUPPORTING MATERIAL
A figure is available at http://www.biophysj.org/biophysj/supplemental/
S0006-3495(11)00787-9.
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